stockaxis

Krishna Institute of Medical Sciences Ltd

Quarterly Result - Q3FY25

Krishna Institute of Medical Sciences Ltd

Hospital & Healthcare Services

Current

CMP
Rs. 605.60
Rating:
Hold
February 06, 2025

Previous

Rating:
Buy

Stock Info

BSE
543308
NSE
KIMS
Bloomberg
KIMS:IN
Reuters
KRII.NS
Sector
Hospital & Healthcare Services
Face Value (Rs)
2
Equity Capital (Rs cr)
80
Mkt Cap (Rs cr)
24136.38
52w H/L (Rs)
674.30 - 350.00
Avg Daily Vol (BSE+NSE)
333,472

Shareholding Pattern

(as on 31-Dec)
%
Promoter
38.82
FIIs
15.68
DIIs
32.05
Public & Others
13.45
Source: Ace equity, stockaxis Research

Price performance

Return (%)
1m
3m
12m
Absolute
3.74
16.88
53.29
Sensex
0.12
-2.89
8.13
Source: Ace equity, stockaxis Research

Indexed Stock Performance

Krishna Institute of Medical Sciences Ltd Sensex
Krishna Institute of Medical Sciences Ltd
Source: Ace equity, stockaxis Research

Financial Highlights:

Particulars (Rs. in cr) Q3FY25 Q3FY24 YoY (%) Q2FY25 QoQ (%)
Revenue from operations 772.00 606.00 28.00% 777.00 -1.00%
EBITDA 187.00 147.00 27.00% 218.00 -14.00%
EBITDA Margin (%) 24.20% 24.30% (3) bps 28.10% (382) bps
PAT 92.00 77.00 21.00% 121.00 -23.00%
EPS (Rs.) 2.22 1.80 23.00% 2.68 -17.00%

Source: Company Filings; stockaxis Research

Q3FY25 Result Highlights
KIMS delivered steady earnings growth for the quarter ended Q3FY25. Consolidated revenues from operations rose 28% YoY to Rs.772 cr as compared to Rs.606 cr registered in the same quarter of the corresponding fiscal. Gross margins stood at 79.05%, contracting marginally by 22bps YoY and 94bps QoQ. Consolidated EBITDA stood at Rs. 187cr, up 27% YoY and -14% QoQ , adjusted for one-time write-offs (8 cr-9 cr). EBITDA margins witnessed a 382 bps QoQ contraction, which was a consequence of lower gross margins in the comparable quarter. Consolidated Profit After Tax stood at Rs. 92cr, up 21% YoY and -23% QoQ, impacted by higher finance costs and lower margin profile during the quarter.

Operational Highlights

  • Consolidated ARPOB stood at Rs. 38,472 vs Rs. 30,741 (up 25.2% YoY), and Rs. 38,263 (-0.8% QoQ) in Q3FY25.
  • Consolidated ARPP stood at Rs. 1,44,181 vs Rs. 1,28,507 (up 12.2% YoY), and Rs. 38,263 (-0.8% QoQ) in Q3FY25.
  • IP Volumes grew by 13.8% YoY and -3.1% QoQ to 54,013.
  • OP volumes grew faster to 4,70,159, up 20% YoY and -0.8% QoQ.

Key Conference Call Takeaways

Guidance:
(i) The Telangana region, which accounts for ~65% of revenues of KIMS, is expected to continue to grow at a similar rate as seen in Q3 (~25%), (ii) the margins are expected to inch up towards 30% post the commencement of operations of many oncology and mother and child hospitals that will come online in FY26, (iii) Targeting a debt to Equity of 0.8-0.9x on a sustainable basis, (iv) Bangalore Expansion: Targeting 2,000 beds over time, with two hospitals opening in FY25 and plans for a third by early FY26. North Bangalore may see an additional 750 beds over 3-4 years. Kerala will also scale up to 2500-3,000 beds over the medium to long term.

Key Milestones

  • An industry first MRI Ultrasound Machine, that offers treatment of Essential Tremors and Parkinsonism-related tremors in minutes.
  • Over 100 robotic assisted surgeries have been done by KIMS to date.
  • Have ordered 25 robots, with 5 already placed in different institutions.
  • Benefits of the robots include Faster recovery, low failure rates, and shorter hospital stays.
  • KIMS’ Maharashtra hospitals have Robotic knee replacement facilities.

Regional Performance

Maharashtra Cluster:

  • Nashik Hospital: Registered a quarterly operating loss of INR 5 Cr. Break-even targeted by end of Q1 FY26 or start of Q2 FY26.
  • Nagpur Hospital: Experienced revenue dip influenced by seasonal factors and write-offs on general dues and PBDT provisions.

Telangana and AP Cluster

  • Growth: Strong volume and revenue growth in both regions for FY25.
  • There is room for Sunshine Hospitals to increase its occupancy which is currently at 60%.
  • AP Cluster: Lower margin profile due to Tier 2 and 3 market presence.

Kerala Cluster

  • Kannur Hospital: Profitable and planning to expand to up to 400 beds in two years.
  • Kollam Hospital: Renovation ongoing and rebranding set for early April FY25.
  • Thrissur Hospital: Operations to begin in 12-15 months, specializing in tertiary and quaternary care.

Sunshine Hospitals (Telangana)

  • Q3FY25 Revenues: 150cr vs 158cr in Q2FY25
  • EBITDA 40cr VS 48cr in Q2FY25
  • Currently operating at 60% occupancy.

Capex and Bed Addition

  • New Facilities in Thane and Bangalore (2 hospitals): Expected to begin operations in early FY26 with initial losses of Rs.10-15 Cr each in FY26, anticipated break-even in FY27.
  • Capex for FY26 guided at Rs.500-600cr

Medical Tourism Revenue

  • Revenue from international patients will be around Rs. 40-50cr in FY25.
  • Expect to generate around 100-150cr in medical tourism from the Telegana Cluster itself.
  • Bangalore and Thane are well-positioned to draw international clientele.

Other Key Points

  • Cash and Equivalents: 112 Cr as of 31st December 2025.
  • Current mix of Therapies is: Cardiac 17-18%, and around ~9-10% each for Renal, Neural, ortho, oncology, and gastro therapies.
  • There is ample scope for growth for new hospitals that are being built to coexist in Thane.
  • Debt as of 31st Dec 2024 stood at Rs. 1,550 cr.
  • International Patients – Expect revenue of Rs.40-50 cr in FY25, with potential growth of Rs.100-150 cr from the Telangana cluster.
  • Management expressed confidence in reaching/achieving FY25 goals and maintain growth via expansion and onboarding strategies.

Outlook & valuation

KIMS delivered a mixed set of numbers for the quarter ended Q3FY25. KIMS’ management pursues a strategy that is fuelled by organic expansion and acquisitions, improving the profitability of acquired businesses, and collaborative partnerships with doctors via equity stakes. KIMS is strategically positioned to bolster its market share by expanding its hospital reach to new geographies. The continuous addition of skilled doctors and advancement of technologies should further boost its vision and performance. We believe that KIMS’ doctor participation model, which focuses on multi-specialty with a well-defined philosophy, execution, and aggressive bed expansion provides a long and sustainable growth path ahead. The initiatives in the core AP-Telangana cluster and the ramp-up of new geography hospitals make it a well-diversified play in the healthcare industry. Incremental initiatives such as the addition of radiation oncology and M&C to further improve ARPOB.

We believe KIMS provides an ideal opportunity to invest in a distinctive multi-specialty hospital chain - 1) Employs a unique approach of a capex light business model in a hospital space with doctors/investor participation, 2) Cost-efficient way of running a hospital, resulting in higher margins, 3) Balanced mix of core and new market expansion, 4) Successful track record of turning around acquisitions and 5) Large scope to improve therapy mix/ARPOB with expansion in oncology, and mother & child.

KIMS Hospitals has a strong trajectory of expansion plans for the next 3 years, which should increase the total bed capacity to 6,300 in FY27, while adding over 2000 beds by FY26. Key hospitals which were acquired a couple of years back like- Sunshine Hospitals (Hyderabad), Kingsway Hospital (Nagpur), and Manavata Hospitals (Nashik) are witnessing a stronger traction and have helped accelerate growth. The recent acquisition of QNRI (Vizag) is set to aid the growth in FY25. A strong growth in operating parameters (IP/OP volume, ARPOB, ARPP) along with multiple expansion plans are likely to boost revenues for KIMS Hospitals going forward. At CMP of Rs.642.25, the stock is trading at 10.7x FY26E. We recommend HOLD rating on the stock.

Consolidated Financial statements

Profit & Loss statement

Particulars (Rs. in cr) Q3FY25 Q3FY24 YoY (%) Q2FY25 QoQ (%)
Revenue from operations 772.00 606.00 28.00% 777.00 -1.00%
COGS 162.00 126.00 29.00% 156.00 4.00%
Gross Profit 611.00 480.00 27.00% 622.00 -2.00%
Gross Margin (%) 79.05% 79.27% (22) bps 79.99% (94) bps
Employee Benefit expense 127.50 104.30 22.00% 119.20 7.00%
Other expenses 296.00 228.90 29.00% 285.00 4.00%
EBITDA 187.00 147.00 27.00% 218.00 -14.00%
EBITDA Margin (%) 24.20% 24.30% (3) bps 28.10% (382) bps
Depreciation and amortisation expenses 44.70 35.40 26.00% 41.00 9.00%
EBIT 143.00 112.00 28.00% 177.00 -20.00%
Finance cost 25.70 12.40 107.00% 19.90 29.00%
Other Income 17.80 3.30 439.00% 5.00 256.00%
PBT 135.00 103.00 31.00% 162.00 -17.00%
Tax expenses 42.10 25.90 63.00% 41.50 1.00%
PAT 92.00 77.00 21.00% 121.00 -23.00%
EPS (Rs.) 2.22 1.80 23.00% 2.68 -17.00%